Collaboration is key—whether we’re growing biotech jobs and startups, or addressing infectious diseases with pandemic potential. Are we ready? Here’s what we learned on Day 1 of the BIO International Convention, and what’s ahead today. Plus, BIO elects a new board…
The only newsletter at the intersection of biotech, politics, and policy
June 6, 2023
Collaboration is key—whether we’re growing biotech jobs and startups, or addressing infectious diseases with pandemic potential. Are we ready? Here’s what we learned on Day 1 of the BIO International Convention, and what’s ahead today. Plus, BIO elects a new board chair and executive committee members. (768 words, 3 minutes, 50 seconds)
How to follow Good Day BIO Live
Follow Bio.News for panel recaps, exclusive Q&As, and much more.
Join the conversation on Twitter with @IAmBiotech and the hashtag #BIO2023. Watch for exclusive video content and repost-worthy quotes, and tell us what you're discovering!
FOMO got you down? It’s not too late to register and hop on over to the Boston Convention and Exhibition Center—click here.
Looking for a CDMO to manufacture your pDNA or mRNA product? Join Wacker Biotech - YOUR Microbial CDMO
- at Booth #1172 and learn more about our expertise in process development and commercial manufacturing of mRNA and PLASMITEC®, our platform in pDNA manufacturing.
The news: The Boston Life Sciences Workforce Initiative aims to connect 1,000 Boston-area residents with life sciences careers by 2025.
The first step: The initial grant application round will provide $4 million for “industry-aligned training and education programs,” as well as programs like internships, hiring commitments, and initiatives for residents without four-year degrees.
What they’re saying: “The regional life sciences industry will need thousands of new workers,” she said. Boston is “the best place in the world to start and grow a life sciences company,” and this initiative will help keep it that way.
We're not ready
On Day 1 of the BIO International Convention, pandemic preparedness—or the lack thereof—came up across panels.
Collaboration is key: “We are not going to be prepared in Europe if we don’t look at the world around us,” said Pierre Delsaux, Director General of the Health Emergency and Preparedness Response Authority (HERA) at the European Commission.
“We really do need a public-private partnership in order for BARDA to be successful,” added Dawn O’Connell, Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), which oversees the Biomedical Advanced Research and Development Authority (BARDA).
The same goes for antimicrobial resistance: “Every other drug we’ve ever invented works forever. The aspirin that was invented 100 years ago still works,” said Kevin Outterson, Executive Director of CARB-X. “For antibiotics, as soon as you start using them, the bacteria respond.”
U.S. and APAC countries grow biotech through cooperation
Here’s what we know: U.S. support for startups—including federal, state, and private efforts—has created a robust ecosystem. Australia has built a booming clinical trial industry, and China anticipates 30% growth in the biotech sector in 5 years.
What they’re saying:“In the last two years, the Japanese government decided to set up supplements of about $10 billion for the biotech industry,” said Yoshiaki Tsukamoto, Executive Director of the Japan Bioindustry Association. “We all know that we’ve experienced a revolution in medicine in the last few years,” said Michelle Ouellette of the U.S. Department of Commerce, saying the pandemic reinforced the need to support biotech and strengthen supply chains.
Innovation requires cross-border cooperation—for the good of economic development, and for the benefits that new medicines bring to humanity, said Jiao Dian, Economy and Commerce Counsellor for the Chinese Embassy to the United States.
BIO: BIO elects Dr. Ted W. Love as new Board Chair “Incoming Chair Dr. Ted Love is a distinguished industry leader with more than two decades of management experience, along with nearly a decade of prior experience as a practicing physician. Dr. Love has spent much of his career focused on addressing the ongoing healthcare disparities facing the sickle cell disease community, and leading the development of therapies for this underserved patient population.”
U.S. House Financial Services Committee: House passes additional slate of bipartisan financial services capital formation legislation “This week, the U.S. House of Representatives passed seven pieces of bipartisan financial services legislation to facilitate capital formation by strengthening public markets, helping small businesses and entrepreneurs, and creating opportunities for all investors. This builds on the four pieces of bipartisan capital formation legislation passed last week” (which Bio.News covered here).
BIO Beltway Report
President Biden’s Tuesday: Holding a Cabinet meeting this afternoon.
What’s Happening on Capitol Hill: ICYMI, the House passed legislation that will help biotech startups and investors—read more.
Biotechnology Innovation Organization (BIO)
1201 New York Avenue NW, Suite 1300, Washington, DC 20005-3972